Real-World Experience with Dolutegravir-Based Two-Drug Regimens.

Douglas WardMoti RamgopalDavid J RiedelCindy GarrisShelly DhirJohn WallerJenna RobertsKatie MycockAlan OglesbyBonnie CollinsMegan DominguezJames PikeJoseph Mrus

Published in: AIDS research and treatment (2020)

Prior to commercial availability of the single-tablet 2DRs, DTG 2DR components were primarily used in treatment-experienced patients for treatment simplification and avoidance of long-term toxicities. Many of these patients achieved and maintained virologic suppression, with low discontinuation rates.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
peritoneal dialysis
prognostic factors
emergency department
patient reported outcomes
hiv infected
drug induced
replacement therapy